DE60331654D1 - Nicht-radioaktives Strontiummittel zur Behandlung von Krebs - Google Patents

Nicht-radioaktives Strontiummittel zur Behandlung von Krebs

Info

Publication number
DE60331654D1
DE60331654D1 DE60331654T DE60331654T DE60331654D1 DE 60331654 D1 DE60331654 D1 DE 60331654D1 DE 60331654 T DE60331654 T DE 60331654T DE 60331654 T DE60331654 T DE 60331654T DE 60331654 D1 DE60331654 D1 DE 60331654D1
Authority
DE
Germany
Prior art keywords
cancer
treatment
radioactive strontium
prophylaxis
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331654T
Other languages
English (en)
Inventor
Thomas Tallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurofood Oy AB
Original Assignee
Neurofood Oy AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurofood Oy AB filed Critical Neurofood Oy AB
Application granted granted Critical
Publication of DE60331654D1 publication Critical patent/DE60331654D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60331654T 2003-10-17 2003-10-17 Nicht-radioaktives Strontiummittel zur Behandlung von Krebs Expired - Lifetime DE60331654D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03103850A EP1523985B1 (de) 2003-10-17 2003-10-17 Nicht-radioaktives Strontiummittel zur Behandlung von Krebs

Publications (1)

Publication Number Publication Date
DE60331654D1 true DE60331654D1 (de) 2010-04-22

Family

ID=34354592

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331654T Expired - Lifetime DE60331654D1 (de) 2003-10-17 2003-10-17 Nicht-radioaktives Strontiummittel zur Behandlung von Krebs

Country Status (11)

Country Link
US (2) US20070031476A1 (de)
EP (1) EP1523985B1 (de)
CN (1) CN1886143B (de)
AT (1) ATE460168T1 (de)
AU (1) AU2004281559B2 (de)
DE (1) DE60331654D1 (de)
DK (1) DK1523985T3 (de)
ES (1) ES2342461T3 (de)
NO (1) NO20062229L (de)
RU (1) RU2363479C2 (de)
WO (1) WO2005037295A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI122450B (fi) * 2007-12-28 2012-01-31 Neurofood Ab Oy Koostumus steriilin inflammaation hoitoon
CN103153267B (zh) * 2010-08-18 2015-07-22 高露洁-棕榄公司 口腔护理产品及其使用和制备方法
FI123756B (fi) * 2010-09-21 2013-10-31 Neurofood Ab Oy Parannettu lisäravinne syövän hoitamiseksi tai ennaltaehkäisemiseksi
EP2530068A1 (de) 2011-05-31 2012-12-05 Lacer, S.A. Neue Strontiumsalze, deren Synthese und Verwendung bei der Behandlung von Osteoporose
WO2013013003A1 (en) * 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
HUE061726T2 (hu) * 2014-07-21 2023-08-28 Oxolife Sl Wolfrám (VI) sók termékenység és reprodukció stimulálására és elõsegített reprodukciós technika hatékonyságának fokozására

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB602029A (en) * 1942-04-17 1948-05-19 Western Condensing Co Improvements in or relating to process of manufacturing a vitamin concentrate
GB602209A (en) * 1945-06-13 1948-05-21 Norton Co Hydraulic table reciprocating mechanism
EP0366869A3 (de) * 1988-10-17 1991-06-12 Lycon Ag Bakteriostatische,Bakterizide und Pilzabweisende Zusammensetzung und Verwendung derselben
CN1082845A (zh) 1992-12-21 1994-03-02 颜怀玮 营养平衡强化型矿泉水及制造方法
CN1053091C (zh) * 1993-03-13 2000-06-07 彭建汉 天然竹汁保健饮料
CN1113720A (zh) * 1994-05-24 1995-12-27 云南智成科技实业公司 保健液及其生产方法
US5650316A (en) * 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
EP0737471A3 (de) * 1995-04-10 2000-12-06 L'oreal Verwendung von Erdalkalimetallsalze als TNF-alpha Inhibitor in einer topischen Zusammensetzung und die so hergestellte Zusammensetzung
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
CN1153053A (zh) * 1995-12-28 1997-07-02 汪贵昌 一种治疗肿瘤的克癌灵中药
US5916143A (en) * 1996-04-30 1999-06-29 Apple; Marc G. Brachytherapy catheter system
CA2339473A1 (en) * 1998-08-04 2000-02-17 John V. Kosbab Nutrient and therapeutic compositions for the treatment of cancer
CA2382262C (en) 1999-08-30 2004-12-07 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
WO2001041821A1 (en) * 1999-12-09 2001-06-14 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US6456680B1 (en) * 2000-03-29 2002-09-24 Tci Incorporated Method of strontium-89 radioisotope production
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
WO2003075957A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Also Published As

Publication number Publication date
US20070031476A1 (en) 2007-02-08
NO20062229L (no) 2006-05-18
EP1523985A1 (de) 2005-04-20
US8703211B2 (en) 2014-04-22
DK1523985T3 (da) 2010-05-31
RU2363479C2 (ru) 2009-08-10
WO2005037295A1 (en) 2005-04-28
AU2004281559A1 (en) 2005-04-28
EP1523985B1 (de) 2010-03-10
CN1886143B (zh) 2011-04-06
CN1886143A (zh) 2006-12-27
ES2342461T3 (es) 2010-07-07
US20100074968A1 (en) 2010-03-25
AU2004281559B2 (en) 2010-04-01
RU2006115785A (ru) 2007-11-27
ATE460168T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
ATE430555T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
DE602005023877D1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
NO20055741L (no) Nye kjemiske forbindelser
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
DE602004023100D1 (de) Verbindungen und verfahren zur behandlung von dyslipidemie
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATA20122001A (de) Verfahren zur behandlung von cellulosischen formkörpern
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
BRPI0409768A (pt) composto, uso de composto, composição farmacêutica, método para tratar e/ou prevenir cáncer, e, processo para preparar o composto
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition